摘要:

AbstractCathepsin D was assayed in 74 primary breast cancer specimens by enzyme immunoassay (EIA) and immunohistochemical assay (ICA). Of the 74 specimens, 38 (51.4%) were scored positive by ICA, and 25 (33.8%) were scored positive by EIA. The coincidence rate between ICA and EIA was 71.6% (53/74). There was no significant correlation between cathepsin D and menopausal status, tumor size, number of metastatic lymph nodes, histologic type of the tumor, or steroid receptor status. Cathepsin D status designated by EIA or ICA predicted neither disease‐free survival (DFS) nor overall survival (OAS). Subset analysis with estrogen receptor, menopausal, and lymph node status revealed no association between cathepsin D and survival. Univariate analysis revealed no association between cathepsin D and DFS or OAS. Therefore, cathepsin D is not an independent prognostic factor in breast cancer. © 1995 Wiley‐Liss,

ISSN:0022-4790    

DOI:10.1002/jso.2930600402

出版商:Wiley Subscription Services, Inc., A Wiley Company    

年代:1995

数据来源: WILEY

摘要:

AbstractBetween 1989 and 1991, 150 patients with ovarian cancer were treated with chemotherapy, including cisplatin, in the Tokai Ovarian Tumor Study Group. Of these patients, 25 underwent cytoreductive surgery with lymphadenectomy, including removal of either pelvic or para‐aortic lymph nodes, and 36 underwent both lymphadenectomies. A significant difference was observed between survival curves of the groups with positive and negative lymph nodes, respectively (P= 0.0049). The overall survival was longer in the lymphadenectomy group than in the nonlymphadenectomy group (P= 0.0842), and a significantly longer survival time was noted for stage III patients who underwent lymphadenectomy compared to those who did not (P= 0.0185). Multivariate analysis demonstrated that lymphadenectomy is a positive prognostic factor. The authors conclude that both pelvic and para‐aortic lymph nodes should be resected to improve survival as well as to assess exact staging in patients with ovarian cancer. © 1995 Wiley‐Lis

ISSN:0022-4790    

DOI:10.1002/jso.2930600403

出版商:Wiley Subscription Services, Inc., A Wiley Company    

年代:1995

数据来源: WILEY

摘要:

AbstractCytogenetic findings of 21 benign salivary gland tumors, including 14 pleomorphic adenomas, 5 Warthin's tumors, 1 myoepithelioma, and 1 cystadenoma, are reported. The present study confirms that pleomorphic adenomas characteristically have highly specific rearrangements involving only a few chromosome regions (3p21, 8q12 and 12q13–15) which suggests their specific role in the mixed tumors genesis. Warthin's tumors also show nonrandom numerical and structural alterations that were concurrent in one of the cases studied. To our knowledge no cytogenetic data are available in myoepitheliomas and cystadenomas. The former reveals a normal karyotype and the latter shows only clonal numerical alterations (gain of chromosomes 2 and 18). © 1995 Wiley‐Liss,

ISSN:0022-4790    

DOI:10.1002/jso.2930600404

出版商:Wiley Subscription Services, Inc., A Wiley Company    

年代:1995

数据来源: WILEY

摘要:

AbstractA pharmacodynamic study of cisplatin (DDP) was conducted using the gastric cancer cell lines MKN‐45 and MKN‐74 in vitro. Ten thousand tumor cells were incubated with 0.4–500 μg/ml DDP for 1–25 h, followed by recovery culture for a further 48 h. At the end of incubation, cell viability was detected by the MTT end‐point, and the inhibition rate was compared in relation to the incubation time, DDP concentration, and the time × concentration product (area under the curve in vitro: AUC vitro). In both of the cell lines, the IC50 and IC90 values decreased as the exposure time increased, going a linear curve with a slope of almost — 1, and showing a typical log‐log AUC vitro‐dependent curve. These results indicate that the antitumor activity of DDP is dependent on its AUC vitro, suggesting the clinical usefulness of this drug when administered daily in small divided doses. © 19

ISSN:0022-4790    

DOI:10.1002/jso.2930600405

出版商:Wiley Subscription Services, Inc., A Wiley Company    

年代:1995

数据来源: WILEY

摘要:

AbstractA prospective randomized study was conducted to compare the adjuvant efficacy of six cycles of high‐dose ACMF (Adriamycin, ADM; cyclophosphamide, CPA; methotrexate, MTX; 5‐fluorouracil, 5‐FU) with that of 12 cycles of low‐dose ACMF in premenopausal, node‐positive breast cancer patients. The six‐cycle ACMF group (93 patients) received, intravenously (iv), 130 mg/m2CPA, 26 mg/m2MTX, and 600 mg/m25‐FU on days 1 and 8, and 26 mg/m2ADM on day 1 of each cycle. The 12‐cycle ACMF group (97 patients) received, iv, 65 mg/m2CPA, 13 mg/m2MTX, and 300 mg/m25‐FU on days 1 and 8, and 13 mg/m2ADM on day 1 of each cycle. These treatments were repeated every 4 weeks, and all the patients took tamoxifen (30 mg/day) for 2 years. The background factors of the two groups were comparable. There were non‐significant trends toward better disease‐free and overall survival rates in the high‐dose, six‐cycle ACMF group. Both treatments were well tolerated, but more patients in the low‐dose, 12‐cycle group refused to continue to receive chemotherapy. These data suggest that escalating doses of ACMF over a shorter period, even with doses within the conventional range, are superior to low‐dose, prolonged

ISSN:0022-4790    

DOI:10.1002/jso.2930600406

出版商:Wiley Subscription Services, Inc., A Wiley Company    

年代:1995

数据来源: WILEY

摘要:

AbstractSurgical treatment of non‐small cell lung cancer has been reported to be associated with increased mortality, especially when pneumonectomy has been employed. A 9‐year review of 81 patients treated surgically, with a policy of avoiding pneumonectomy and using internal radiation and wedge excisions rather than lobectomy among patients with impaired reserve, resulted in an operative mortality of 4.9% compared with an overall mortality of 2.1%. Three of the four deaths were among patients older than 80 3/17 (17.6%) years so that mortality of patients 70

ISSN:0022-4790    

DOI:10.1002/jso.2930600407

出版商:Wiley Subscription Services, Inc., A Wiley Company    

年代:1995

数据来源: WILEY

摘要:

AbstractThis paper describes 29 patients with Ewing's sarcoma of bone treated between 1975 and 1990 at the University of Nijmegen Hospital, Nijmegen, The Netherlands. Osteomyelitis was the primary diagnosis in 24%.Treatment consisted of chemotherapy in combination with surgery and/or radiotherapy. Nine patients received radiotherapy only; five of them died of disease. Five patients underwent an intralesional excision; four of them died of disease. Twelve patients underwent a wide excision; there is no evidence of disease in any of them. Three patients underwent a radical disarticulation; all died of disease. The disease‐free survival at 1.5 years was 66%. This figure at 5 years was 55%. After wide excision and reconstruction in tumors of expendable, femoral or radial bones good functional results were obtained in all cases. © 1995 Wiley‐Liss,

ISSN:0022-4790    

DOI:10.1002/jso.2930600408

出版商:Wiley Subscription Services, Inc., A Wiley Company    

年代:1995

数据来源: WILEY

摘要:

AbstractComplete surgical resection of stage III non‐small cell lung cancer (NSCLC) is at times impossible. Adjuvant radiation therapy is required to sterilize the residual tumor. This study is to investigate the safety, reproducibility, and effectiveness of intraoperative I–125 or Pd‐103 Gelfoam plaque implant technique as an adjuvant treatment for resected stage III NSCLC with positive surgical margin. Between 1989 and 1993, 12 patients with stage III NSCLC received intraoperative lung implant with radioactive I–125 or Pd‐103 pellets. All 12 patients underwent tumor resection, but either gross or microscopic positive margin was found during operation. Radioactive I‐125 or Pd‐103 seeds were embedded in the Gelfoam plaque. After surgical resection was completed, the radioactive Gelfoam plaque was secured onto the tumor bed either by clips or suture. Either preoperative or postoperative external beam radiation of 45–60 Gy was given to all of the 12 patients. Four patients received chemotherapy. No patient has developed any early or late complications attributable to implant procedure or radiation. The local control rate at last follow‐up is 82%. The 2‐year overall and cause‐specific survival rates are 45% and 56%, respectively. The intraoperative Gelfoam I‐125 or Pd‐103 planar implant technique is a safe, reproducible, and effective technique of treatment for stage III NSCLC with positive surgical margin. Encouraging local control and survival are achieved in patients treated with this technique. This technique will compliment standard adjuvant treatments to further improve local control in resected stage III lung cance

ISSN:0022-4790    

DOI:10.1002/jso.2930600409

出版商:Wiley Subscription Services, Inc., A Wiley Company    

年代:1995

数据来源: WILEY

摘要:

AbstractFrom 1986 to 1993, 15 patients with malignant pleural mesothelioma were treated by pleurectomy/decortication and intrapleural cisplatin (100 mg/ m2) and cytosine arabinoside (1,200 mg). All patients were without known extrathoracic disease and had a mean age of 63.5 ± 7.9 years (range 51–78); 13 were male. Histologic subtype of disease were epithelial (47%), sarcomatoid (27%), and mixed‐biphasic (27%). The major morbidity and mortality rates were 13% and 0%, respectively. The mean length of hospital stay was 6.5 ± 2.1 days. Postoperatively, adjuvant chemotherapy and radiation therapy were given to 46% and 73% of the patients respectively. Median survival from date of treatment was 11.5 months. Those patients with an epithelial histologic subtype experienced significantly improved survival compared to those of sarcomatoid subtype (P= 0.024). Whether adjuvant chemotherapy or radiation therapy were given had no significant effect on survival. These data suggest that although this treatment regimen can be administered with very limited morbidity and no mortality, the role of this approach in the treatment of malignant pleural mesothelioma appears limited and cannot currently be recommended. © 1995 Wiley‐L

ISSN:0022-4790    

DOI:10.1002/jso.2930600410

出版商:Wiley Subscription Services, Inc., A Wiley Company    

年代:1995

数据来源: WILEY

摘要:

AbstractOne hundred sixty‐eight patients treated at Hacettepe Hospital between 1969–1993 with metastatic ovarian tumors constituted 21.5% of all malignant ovarian neoplasms. Primary tumors were endometrial (51), breast (27), colorectal (18), and stomach cancer (17), lymphoma (14), sarcoma of the uterus (13), undetermined (11), tumors of the appendix (6) and ileum (4), carcinoma of the cervix (4), and gestational trophoblastic neoplasia (3). Overall 5‐year and median survivals were 20.0% and 26.8 months, respectively. While worse prognoses were seen in gastric cancer and undetermined tumors followed by colorectal cancer, best survival figures were observed in endometrial cancer patients. A trend toward a better survival was seen with the advancement of the operation from bilateral salpingooophorectomy and/or biopsy to total abdominal hysterectomy, bilateral salpingooophorectomy, total omentectomy and pelvic and paraaortic lymphadenectomy with debulking. Multivariate analysis identified the primary site, grade, laterality of involvement, type of surgery and adjuvant therapy status as significant prognostic parameters. Maximal surgical effort followed by adjuvant therapy might at least have short term survival benefit in certain types metastatic to the ovaries. © 1995 Wiley‐L

ISSN:0022-4790    

DOI:10.1002/jso.2930600411

出版商:Wiley Subscription Services, Inc., A Wiley Company    

年代:1995

数据来源: WILEY